Published in Lupus on May 02, 2014
Immunotherapies for Immune-Mediated Myopathies: A Current Perspective. Neurotherapeutics (2016) 0.85
Direct effects of HP Acthar Gel on human B lymphocyte activation in vitro. Arthritis Res Ther (2015) 0.78
Adrenocorticotropic hormone gel in the treatment of systemic lupus erythematosus: A retrospective study of patients. F1000Res (2015) 0.75
Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel. Respir Med Case Rep (2015) 0.75
Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study. Lupus Sci Med (2016) 0.75
Systemic lupus erythematosus. N Engl J Med (2011) 7.79
Systemic lupus erythematosus disease activity index 2000. J Rheumatol (2002) 6.11
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis (2007) 3.32
Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system. Adv Anat Embryol Cell Biol (2012) 2.99
Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev (2000) 2.98
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) (2005) 2.37
Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev (2004) 2.08
High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics (1996) 2.03
Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum (1999) 1.87
Key role of CRF in the skin stress response system. Endocr Rev (2013) 1.77
Steroidogenesis in the skin: implications for local immune functions. J Steroid Biochem Mol Biol (2013) 1.71
Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents. J Immunol (1998) 1.51
Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des Devel Ther (2011) 1.29
The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford) (2011) 1.25
International consensus for a definition of disease flare in lupus. Lupus (2010) 1.16
Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. Drug Des Devel Ther (2012) 1.12
Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum (2008) 1.07
Quality of life in systemic lupus erythematosus: a controlled study. J Rheumatol (1999) 1.00
BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000. Ann Rheum Dis (2007) 0.99
Systemically administered alpha-melanocyte-stimulating peptides inhibit NF-kappaB activation in experimental brain inflammation. Brain Res (1999) 0.93
Five-day regimen of intramuscular or subcutaneous self-administered adrenocorticotropic hormone gel for acute exacerbations of multiple sclerosis: a prospective, randomized, open-label pilot trial. Drug Des Devel Ther (2011) 0.89
Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trial. J Rheumatol (2011) 0.88
Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider. Clin Exp Rheumatol (2012) 0.85
The use of glucocorticoids in systemic lupus erythematosus. After 60 years still more an art than science. Autoimmun Rev (2012) 0.85
Pituitary-adrenal responsiveness to corticotropin-releasing hormone in patients receiving chronic, alternate day glucocorticoid therapy. J Clin Endocrinol Metab (1985) 0.84
Qualitative validation of the FACIT-fatigue scale in systemic lupus erythematosus. Lupus (2013) 0.82
Cerebrospinal fluid ACTH and cortisol in opsoclonus-myoclonus: effect of therapy. Pediatr Neurol (2005) 0.81